MktsMarkets

Telomir Pharmaceuticals, Inc.
NASDAQ: TELOKey statistics
TELO News
Stories mentioning TELO from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 468.00 | 1,296 | 760.00 | 43.00 | 337.00 | 209.00 | 627.00 | 595.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 1,041 | 2,135 | 1,146 | 5,070 | 2,188 | 2,846 | 6,006 | 1,474 |
| Operating Income (Loss) | 2,188 | |||||||
| Interest Income | 52.00 | 73.00 | 44.00 | 1.00 | 8.00 | 15.00 | 25.00 | |
| Interest Expense | ||||||||
| Other Expense | 50.00 | 8.00 | ||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (991.00) | (2,061) | (1,102) | (5,070) | (2,180) | (2,898) | (5,991) | (1,389) |
| Earnings Per Share (Basic) | (0.03) | (0.07) | (0.03) | 0.17 | (0.07) | (0.10) | (0.20) | 0.05 |
| Earnings Per Share (Diluted) | (0.03) | (0.07) | (0.03) | 0.17 | (0.07) | (0.10) | (0.20) | 0.05 |
| Weighted Average Shares Outstanding (Basic) | 34,381 | 31,653 | 32,399 | 30,010 | 29,763 | 29,539 | 29,610 | 29,610 |
| Weighted Average Shares Outstanding (Diluted) | 34,381 | 31,653 | 32,399 | 30,010 | 29,763 | 29,539 | 29,610 | 29,610 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TELO
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a stock listed on the Nasdaq Stock Market under the ticker symbol TELO. It last traded at $0.6900 (Nov 9, 2026, 4:00 PM ET), down 2.8% on the day. That gives Telomir Pharmaceuticals a market capitalisation of $52.3M.
Over the past 52 weeks TELO has traded between $0.6900 and $1.58.
For the quarter ended Mar 31, 2026 it reported a net loss of $991.0K.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$991.0K |
| Dec 31, 2025 | — | -$2.1M |
| Sep 30, 2025 | — | -$1.1M |
| Jun 30, 2025 | — | -$5.1M |
From Telomir Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…